Chris Ryan

3 weeks ago | onclive.com | Chris Ryan

A new drug application (NDA) has been submitted to the FDA seeking the approval of vepdegestrant for the treatment of patients with estrogen receptor (ER)–positive, HER2-negative advanced or metastatic breast cancer harboring an ESR1 mutation who were previously treated with endocrine-based therapy.1The NDA is supported by data from the phase 3 VERITAC-2 trial (NCT05654623).

3 weeks ago | onclive.com | Chris Ryan

The 2025 EHA Congress will spotlight some of the top data and research emerging across the hematologic oncology field. To prepare for this year’s meeting, OncLive® asked experts to outline the most anticipated data and research being presented in Milan, Italy. Exclusive insights were gathered from:Naval G.

3 weeks ago | onclive.com | Chris Ryan

Fact checked by:The FDA granted breakthrough therapy designation to iopofosine I 131 for relapsed/refractory Waldenström macroglobulinemia. The FDA has granted breakthrough therapy designation to iopofosine I 131 for the treatment of patients with relapsed/refractory Waldenström macroglobulinemia.1Iopofosine I 131 is a potential first-in-class, novel agent that features a phospholipid ether as a radioconjugate monotherapy.

3 weeks ago | onclive.com | Chris Ryan

The addition of IMNN-001 to neoadjuvant and adjuvant chemotherapy led to numerical improvements in progression-free survival (PFS) and overall survival (OS) compared with perioperative chemotherapy alone in patients with newly diagnosed epithelial ovarian cancer, according to data from the phase 1/2 OVATION-2 trial (NCT03393884).1 Findings presented at the 2025 ASCO Annual Meeting showed that at a median follow-up of 24 months, patients in the intention-to-treat (ITT) population given...

3 weeks ago | onclive.com | Chris Ryan

The National Comprehensive Cancer Network (NCCN) has updated its Guidelines for Colorectal Cancer (CRC) Screening to include both the ColoSense test and the Shield blood test.1-3 ColoSense Background ColoSense is a noninvasive stool-based test intended to detect CRC and advanced adenomas in average-risk patients 45 years of age and older.1 In May 2024, the FDA approved ColoSense as a screening test for adults 45 years of age or older who are at typical average risk for developing CRC.4 “The...